secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001628280-25-046763
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma appoints Dr. Ted Love to board; director Kenneth O'Keefe to retire Dec 1, 2025
--------------------------------------------------------------------------------

- Dr. Ted Love appointed as Class I director effective Dec 1, 2025, term expiring at 2027 AGM.
- Love will serve on Audit and Science & Medicine Committees under standard non-employee director compensation.
- Director Kenneth O'Keefe retires from Board effective Dec 1, 2025, with no dispute or disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000162828025046763/0001628280-25-046763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000162828025046763/jazz-20251023.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-046763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer